Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
03 Enero 2023 - 3:05PM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell
reprogramming company dedicated to developing curative cell
therapies for patients with solid tumors, announced today that
members of its senior management team will present and participate
in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday,
January 10 at 4:30 pm Pacific Time.
At the conference, Lyell executives will
highlight the company’s growing pipeline of product candidates
targeting solid tumors and T-cell reprogramming technologies,
including its:
- Lead CAR T cell
and TIL product candidates, LYL797 and LYL845, which are in Phase 1
clinical development;
-
Second-generation ROR1 targeting CAR T-cell product candidate,
LYL119, that incorporates two new reprogramming technologies
- Newest stackable
genetic and epigenetic reprogramming technologies:
- NR4A3 gene
knockout, that is being incorporated along with c-Jun
overexpression to enhance the functional activity of CAR T cells;
and
- Stim-RTM, a
programmable cell-signaling platform that optimizes signaling
parameters during T-cell activation in order to generate more
potent CAR T cells
A live webcast of the presentation can be
accessed through the Investors section of the Company's website at
www.lyell.com. Following the live presentation, a replay of the
webcast will be available on the Company's website for 30 days
following the presentation date.
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company advancing a pipeline of therapies designed to address what
it believes are the primary barriers that limit consistent and
long-lasting responses to adoptive T-cell therapy: T cell
exhaustion and lack of durable stemness, which includes the ability
to persist and self-renew to drive durable tumor cytotoxicity.
Lyell is applying its proprietary ex vivo genetic and epigenetic
reprogramming technologies to address these barriers in order to
develop new medicines with improved and durable clinical outcomes.
Lyell is based in South San Francisco, California with facilities
in Seattle and Bothell, Washington. To learn more, please visit
www.lyell.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements expressed or implied
in this press release include, but are not limited to, statements
regarding: Lyell’s anticipated progress, business plans, business
strategy, planned research and clinical trials and plans to present
at the conference; the growing pipeline of product candidates and
T-cell reprogramming technologies and the potential clinical
benefits and therapeutic potential of such product candidates and
technologies; the potential of Lyell’s reprogramming technologies
to overcome primary barriers to successful adoptive cell therapy in
solid tumors, including the ability for Lyell’s new genetic and
epigenetic reprogramming technologies to enhance the functional
activity of CAR T cells and to generate more potent CAR T cells,
and Lyell’s plans for such reprogramming technologies; and other
statements that are not historical fact. These statements are based
on Lyell’s current plans, objectives, estimates, expectations and
intentions, are not guarantees of future performance and inherently
involve significant risks and uncertainties. Actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, but are not limited to, risks and
uncertainties related to: the effects of the COVID-19 pandemic;
geopolitical instability; macroeconomic conditions; Lyell’s ability
to submit planned INDs or initiate or progress clinical trials on
the anticipated timelines, if at all; Lyell’s lack of experience as
a company in enrolling, conducting or completing clinical trials;
Lyell’s ability to manufacture and supply its product candidates
for its clinical trials; the preclinical profiles of Lyell’s
product candidates not translating in clinical trials; the
potential for results from clinical trials to differ from
preclinical, early clinical, preliminary or expected results;
significant adverse events, toxicities or other undesirable side
effects associated with Lyell’s product candidates; the significant
uncertainty associated with Lyell’s product candidates ever
receiving any regulatory approvals; Lyell’s ability to obtain,
maintain or protect intellectual property rights related to its
product candidates; implementation of Lyell’s strategic plans for
its business and product candidates; the sufficiency of Lyell’s
capital resources and need for additional capital to achieve its
goals; and other risks, including those described under the heading
“Risk Factors” in Lyell’s most recently filed quarterly report on
Form 10-Q and subsequent filings with the Securities and
Exchange Commission. Forward-looking statements contained in this
press release are made as of this date, and Lyell undertakes no
duty to update such information except as required under applicable
law.
Contact:
Ellen RoseSenior Vice President, Communications
and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Lyell Immunopharma (NASDAQ:LYEL)
Gráfica de Acción Histórica
De May 2023 a May 2024